Drugs Details

Drugs Info of Carafate
Drugs Details
  • Drugs Type  : FDA
  • Date : 6th Jan 2015 02:57 am
  • Brand Name : Carafate
  • Generic Name : sucralfate (oral) (Pronunciation: soo KRAL fate)
Descriptions

CARAFATE Tablets contain sucralfate and sucralfate is an a-D-glucopyranoside, β-D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex.

Carafate (sucralfate) structural formula illustration

Tablets for oral administration contain 1 g of sucralfate.

Also contain: D & C Red #30 Lake, FD&C Blue #1 Lake, magnesium stearate, microcrystalline cellulose, and starch. Therapeutic category: antiulcer.

What are the possible side effects of sucralfate (Carafate)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

  • nausea, vomiting, upset stomach;
  • stomach pain;
  • constipation, diarrhea;
  • mild itching or skin rash;
  • sleep problems (insomnia);
  • dizziness, drowsiness, spinning sensation;
  • headache; or
  • back pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side...

Read All Potential Side Effects and See Pictures of Carafate Tablets »

What are the precautions when taking sucralfate (Carafate Tablets)?

Before taking sucralfate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney problems, swallowing problems (such as difficulty swallowing, history of aspiration), stomach/intestine problems (e.g., delayed gastric emptying), tube feeding, use of a breathing tube (tracheotomy).

Kidney function declines as you grow older. This medication contains aluminum, which is normally removed by your kidneys. Therefore, elderly people may be at greater risk for developing high aluminum levels while...

Read All Potential Precautions of Carafate Tablets »

This monograph has been modified to include the generic and brand name in many instances.

Indications

CARAFATE® (sucralfate) is indicated in:

  • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.
  • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

Dosage Administration

Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g four times per day on an empty stomach.

Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after sucralfate.

While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.

Maintenance Therapy: The recommended adult oral dosage is 1 g twice a day.

Elderly: In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See PRECAUTIONS Geriatric Use)

How Supplied

CARAFATE (sucralfate) 1 g tablets are supplied in bottles of 100 (NDC 58914-171-10), 120 (NDC 58914-171-21), and 500 (NDC 58914-171-50). Light pink, scored, oblong tablets are embossed with CARAFATE (sucralfate) on one side and 1712 on the other.

Axcan Scandipharm Inc. 22 Inverness Center, Parkway, Birmingham, AL 35242. www.axcan.com.
FDA Rev date: 4/26/2007

This monograph has been modified to include the generic and brand name in many instances.

Side Effects

Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%).

Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system:

Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth

Dermatological: pruritus, rash

Nervous System: dizziness, insomnia, sleepiness, vertigo

Other: back pain, headache

Postmarketing reports of hypersensitivity reactions, including urticaria (hives), angioedema, respiratory difficulty, rhinitis, laryngospasm, and facial swelling have been reported in patients receiving sucralfate tablets. Similar events were reported with sucralfate suspension. However, a causal relationship has not been established.

Bezoars have been reported in patients treated with sucralfate. The majority of patients had underlying medical conditions that may predispose to bezoar formation (such as delayed gastric emptying) or were receiving concomitant enteral tube feedings.

Inadvertent injection of insoluble sucralfate and its insoluble excipients has led to fatal complications, including pulmonary and cerebral emboli. Sucralfate is not intended for intravenous administration.

Read the Carafate Tablets (sucralfate) Side Effects Center for a complete guide to possible side effects

Learn More »

Interactions

Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy.

The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction. Because of the potential of CARAFATE (sucralfate) to alter the absorption of some drugs, CARAFATE (sucralfate) should be administered separately from other drugs when alterations in bioavailability are felt to be critical. In these cases, patients should be monitored appropriately.

Read the Carafate Tablets Drug Interactions Center for a complete guide to possible interactions

Learn More »

This monograph has been modified to include the generic and brand name in many instances.

Warnings

No information provided.

Precautions

Duodenal ulcer is a chronic, recurrent disease. While short-term treatment with sucralfate can result in complete healing of the ulcer, a successful course of treatment with sucralfate should not be expected to alter the posthealing frequency or severity of duodenal ulceration.

Special Populations: Chronic Renal Failure and Dialysis Patients

When sucralfate is administered orally, small amounts of aluminum are absorbed from the gastrointestinal tract. Concomitant use of sucralfate with other products that contain aluminum, such as aluminum-containing antacids, may increase the total body burden of aluminum. Patients with normal renal function receiving the recommended doses of sucralfate and aluminum-containing products adequately excrete aluminum in the urine. Patients with chronic renal failure or those receiving dialysis have impaired excretion of absorbed aluminum. In addition, aluminum does not cross dialysis membranes because it is bound to albumin and transferrin plasma proteins. Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia, encephalopathy) have been described in patients with renal impairment. Sucralfate should be used with caution in patients with chronic renal failure.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Chronic oral toxicity studies of 24 months' duration were conducted in mice and rats at doses up to 1 g/kg (12 times the human dose).

There was no evidence of drug-related tumorigenicity. A reproduction study in rats at doses up to 38 times the human dose did not reveal any indication of fertility impairment. Mutagenicity studies were not conducted.

Pregnancy

Teratogenic effects. Pregnancy Category B.

Teratogenicity studies have been performed in mice, rats, and rabbits at doses up to 50 times the human dose and have revealed no evidence of harm to the fetus due to sucralfate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

Clinical studies of CARAFATE (sucralfate) Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See DOSAGE AND ADMINISTRATION)

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. (See PRECAUTIONS Special Populations: Chronic Renal Failure and Dialysis Patients) Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

This monograph has been modified to include the generic and brand name in many instances.

OverDose

Due to limited experience in humans with overdosage of sucralfate, no specific treatment recommendations can be given. Acute oral toxicity studies in animals, however, using doses up to 12 g/kg body weight, could not find a lethal dose. Sucralfate is only minimally absorbed from the gastrointestinal tract. Risks associated with acute overdosage should, therefore, be minimal. In rare reports describing sucralfate overdose, most patients remained asymptomatic. Those few reports where adverse events were described included symptoms of dyspepsia, abdominal pain, nausea, and vomiting.

ContrainDications

There are no known contraindications to the use of sucralfate.

This monograph has been modified to include the generic and brand name in many instances.

Clinical Pharamacology

Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine.

Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be fully defined, it is known that it exerts its effect through a local, rather than systemic, action. The following observations also appear pertinent:

  1. Studies in human subjects and with animal models of ulcer disease have shown that sucralfate forms an ulcer-adherent complex with proteinaceous exudate at the ulcer site.
  2. In vitro, a sucralfate-albumin film provides a barrier to diffusion of hydrogen ions.
  3. In human subjects, sucralfate given in doses recommended for ulcer therapy inhibits pepsin activity in gastric juice by 32%.
  4. In vitro, sucralfate adsorbs bile salts.

These observations suggest that sucralfate's antiulcer activity is the result of formation of an ulcer-adherent complex that covers the ulcer site and protects it against further attack by acid, pepsin, and bile salts. There are approximately 14 to 16 mEq of acid-neutralizing capacity per 1 g dose of sucralfate.

Clinical Trials

Acute Duodenal Ulcer

Over 600 patients have participated in well-controlled clinical trials worldwide. Multicenter trials conducted in the United States, both of them placebo-controlled studies with endoscopic evaluation at 2 and 4 weeks,showed:

STUDY 1


Treatment Groups Ulcer Healing/ No. Patients
  2 wk 4 wk (Overall)
Sucralfate 37/105 (35.2%) 82/109 (75.2%)
Placebo 26/106 (24.5%) 68/107 (63.6%)

STUDY 2


Treatment Groups Ulcer Healing/ No. Patients
  2 wk 4 wk (Overall)
Sucralfate 8/24 (33%) 22/24 (92%)
Placebo 4/31 (13%) 18/31 (58%)

The sucralfate-placebo differences were statistically significant in both studies at 4 weeks but not at 2 weeks. The poorer result in the first study may have occurred because sucralfate was given 2 hours after meals and at bedtime rather than 1 hour before meals and at bedtime, the regimen used in international studies and in the second United States study. In addition, in the first study liquid antacid was utilized as needed, whereas in the second study antacid tablets were used.

Maintenance Therapy After Healing of Duodenal Ulcer

Two double-blind randomized placebo-controlled U.S. multicenter trials have demonstrated that sucralfate (1 g bid) is effective as maintenance therapy following healing of duodenal ulcers.

In one study, endoscopies were performed monthly for 4 months. Of the 254 patients who enrolled, 239 were analyzed in the intention-to-treat life table analysis presented below.

Duodenal Ulcer Recurrence Rate (%)


Drug Months of Therapy
  n 1 2 3 4
CARAFATE 122 20* 30* 38† 42†
Placebo 117 33 46 55 63
*P<0.05
†P<0.01

In this study, prn antacids were not permitted.

In the other study, scheduled endoscopies were performed at 6 and 12 months, but for-cause endoscopies were permitted as symptoms dictated. Median symptom scores between the sucralfate and placebo groups were not significantly different. A life table intention-to-treat analysis for the 94 patients enrolled in the trial had the following results:

Duodenal Ulcer Recurrence Rate (%)


Drug n 6 months 12 months
CARAFATE 48 19* 27*
Placebo 46 54 65
*P<0.002

In this study, prn antacids were permitted.

Data from placebo-controlled studies longer than 1 year are not available.

This monograph has been modified to include the generic and brand name in many instances.

Patient Information

No information provided. Please refer to the PRECAUTIONS section.

This monograph has been modified to include the generic and brand name in many instances.

Consumer Overview Uses

IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

 

SUCRALFATE - ORAL

 

(soo-KRAL-fate)

 

COMMON BRAND NAME(S): Carafate

 

USES: This medication is used to treat and prevent ulcers in the intestines. Sucralfate forms a coating over ulcers, protecting the area from further injury. This helps ulcers heal more quickly.

 

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

This drug may also be used to treat and prevent ulcers in the stomach, and to prevent ulcers caused by the use of aspirin or other anti-inflammatory drugs (e.g., ibuprofen, naproxen).

 

HOW TO USE: Take this medicine by mouth, usually 2 to 4 times daily, on an empty stomach at least 1 hour before a meal, or as directed by your doctor.

The dosage is based on your medical condition and response to therapy.

Use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same times each day. It is important to continue taking this medication even if you do not feel ulcer pain. Do not stop taking this medication without consulting your doctor. It may take 4 to 8 weeks for your ulcer to heal completely.

Some medications may not work as well if you take them at the same time as sucralfate. They may need to be taken at a different time of the day than the time you take sucralfate. Ask your doctor or pharmacist for help making a dosing schedule that will work with all your medications.

Antacids can be used with this medicine, but they should be taken at least 30 minutes before or after sucralfate.

Inform your doctor if your condition persists or worsens after you have been taking sucralfate for 4 weeks.

Consumer Overview Side Effect

SIDE EFFECTS: Constipation, dry mouth, upset stomach, gas, and nausea may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: an unusual/persistent feeling of fullness in the stomach, nausea/vomiting/stomach pain especially after meals, difficulty swallowing.

A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.

This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.

In the US -

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

 

Read the Carafate Tablets (sucralfate) Side Effects Center for a complete guide to possible side effects

Learn More »

PRECAUTIONS: Before taking sucralfate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney problems, swallowing problems (such as difficulty swallowing, history of aspiration), stomach/intestine problems (e.g., delayed gastric emptying), tube feeding, use of a breathing tube (tracheotomy).

Kidney function declines as you grow older. This medication contains aluminum, which is normally removed by your kidneys. Therefore, elderly people may be at greater risk for developing high aluminum levels while using this drug with other products that contain aluminum (e.g., antacids).

If you are pregnant, tell your doctor before using sucralfate.

It is not known if this medication passes into breast milk. Consult your doctor before breast-feeding.

Consumer Overview Missed Dose

DRUG INTERACTIONS: Your healthcare professionals (e.g., doctor or pharmacist) may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop or change the dosage of any medicine before checking with them first.

Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: antacids that contain aluminum, certain antibiotics (e.g., quinolones such as ciprofloxacin/levofloxacin/ofloxacin, tetracyclines), cimetidine, digoxin, ketoconazole, penicillamine, phenytoin, quinidine, ranitidine, theophylline, thyroid medications (e.g., levothyroxine, liothyronine).

This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.

 

OVERDOSE: If overdose is suspected, contact a poison control center or emergency room immediately. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.

 

NOTES: Your doctor may recommend some lifestyle changes such as stress-reducing programs, diet changes and exercise to assist in treatment and prevention of ulcers.

Do not share this medication with others.

 

MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

 

STORAGE: Store at room temperature between 68-77 degrees F (20-25 degrees C) away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.

Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

 

Information last revised March 2014. Copyright(c) 2014 First Databank, Inc.

Patient Detailed Side Effect

Brand Names: Carafate

Generic Name: sucralfate (oral) (Pronunciation: soo KRAL fate)

  • What is sucralfate (Carafate Tablets)?
  • What are the possible side effects of sucralfate (Carafate Tablets)?
  • What is the most important information I should know about sucralfate (Carafate Tablets)?
  • What should I discuss with my healthcare provider before taking sucralfate (Carafate Tablets)?
  • How should I take sucralfate (Carafate Tablets)?
  • What happens if I miss a dose (Carafate Tablets)?
  • What happens if I overdose (Carafate Tablets)?
  • What should I avoid while taking sucralfate (Carafate Tablets)?
  • What other drugs will affect sucralfate (Carafate Tablets)?
  • Where can I get more information?

What is sucralfate (Carafate Tablets)?

Sucralfate is an anti-ulcer medication.

Sucralfate is not greatly absorbed into the body through the digestive tract. It works mainly in the lining of the stomach by adhering to ulcer sites and protecting them from acids, enzymes, and bile salts.

Sucralfate is used to treat an active duodenal ulcer. Sucralfate can heal an active ulcer, but it will not prevent future ulcers from occurring.

Sucralfate may also be used for purposes not listed in this medication guide.

Carafate 1 gram

oblong, pink, imprinted with CARAFATE, 17 12

What are the possible side effects of sucralfate (Carafate Tablets)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects may include:

  • nausea, vomiting, upset stomach;
  • stomach pain;
  • constipation, diarrhea;
  • mild itching or skin rash;
  • sleep problems (insomnia);
  • dizziness, drowsiness, spinning sensation;
  • headache; or
  • back pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the Carafate Tablets (sucralfate) Side Effects Center for a complete guide to possible side effects

Learn More »

What is the most important information I should know about sucralfate (Carafate Tablets)?

Before taking sucralfate, tell your doctor if you have diabetes, kidney disease, or if you are on dialysis.

Take sucralfate on an empty stomach, at least 1 hour before or 2 hours after a meal.

Take this medicine for the full prescribed length of time. Your symptoms may improve before the ulcer is completely healed.

Avoid taking any other medications within 2 hours before or after you take sucralfate. Sucralfate can make it harder for your body to absorb other medications you take by mouth.

Avoid using antacids without your doctor's advice. Use only the type of antacid your doctor recommends. Some antacids can make it harder for sucralfate to work in your stomach. If your doctor does recommend using an antacid, avoid taking it within 30 minutes before or after taking sucralfate.

Side Effects Centers
  • Carafate
  • Carafate Suspension

Patient Detailed How Take

What should I discuss with my healthcare provider before taking sucralfate (Carafate Tablets)?

To make sure you can safely take sucralfate, tell your doctor if you have any of these other conditions:

  • diabetes;
  • kidney disease; or
  • if you are on dialysis.

FDA pregnancy category B. This medication is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment.

It is not known whether sucralfate passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take sucralfate (Carafate Tablets)?

Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

Take sucralfate on an empty stomach, at least 1 hour before or 2 hours after a meal.

Shake the oral suspension (liquid) well just before you measure a dose. Measure the liquid with a special dose-measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

Take this medicine for the full prescribed length of time. Your symptoms may improve before the ulcer is completely healed.

Store at room temperature away from moisture and heat.

Side Effects Centers
  • Carafate
  • Carafate Suspension

Patient Detailed Avoid Taking

What happens if I miss a dose (Carafate Tablets)?

Take the missed dose as soon as you remember, but avoid taking any other medications within 2 hours after you take sucralfate. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose (Carafate Tablets)?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking sucralfate (Carafate Tablets)?

Avoid taking any other medications within 2 hours before or after you take sucralfate. Sucralfate can make it harder for your body to absorb other medications you take by mouth.

Avoid using antacids without your doctor's advice. Use only the type of antacid your doctor recommends. Some antacids can make it harder for sucralfate to work in your stomach. If your doctor does recommend using an antacid, avoid taking it within 30 minutes before or after taking sucralfate.

What other drugs will affect sucralfate (Carafate Tablets)?

Sucralfate can make it harder for your body to absorb other medications you take by mouth. Tell your doctor if you are taking:

  • cimetidine (Tagamet);
  • digoxin (digitalis, Lanoxin);
  • levothyroxine (Synthroid);
  • phenytoin (Dilantin);
  • quinidine (Quin-G);
  • ranitidine (Zantac);
  • tetracycline (Ala-Tet, Brodspec, Panmycin, Sumycin, Tetracap);
  • theophylline (Elixophyllin, Theo-24, Theochron, Uniphyl, and others);
  • a blood thinner such as warfarin (Coumadin, Jantoven); or
  • certain antibiotics such as ciprofloxacin (Cipro), levofloxacin (Levaquin), lomefloxacin (Maxaquin), ketoconazole (Nizoral), and others.

This list is not complete and other drugs may interact with sucralfate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Where can I get more information?

Your pharmacist can provide more information about sucralfate.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 7.01. Revision date: 9/12/2011.

Your use of the content provided in this service indicates that you have read,understood and agree to the End-User License Agreement,which can be accessed by clicking on this link.

Healthwise

Side Effects Centers
  • Carafate
  • Carafate Suspension

Rx Scoops
Featured Topics
Advertisements
Copyrights ©2014: Rx Scoops - Designed & Developed By - GOIGI